The GLP-1 Boom Is Reshaping Who Gets Access to Weight-Loss Drugs

A new class of weekly injections has reshaped obesity treatment faster than almost any drug in recent memory. Now insurers, employers, and health systems are scrambling to figure out who should actually get access, and who pays.

GLP-1 receptor agonists, originally developed to manage diabetes, produce weight loss substantial enough that they’ve become the most in-demand pharmaceutical category in years. Clinical trial data consistently shows patients losing a meaningful share of body weight, results that dwarf almost anything previously available outside of surgery.

The demand has been so intense that manufacturers have struggled to keep up, leading to recurring shortages that have left patients managing chronic conditions competing for supply against a much larger population seeking the drugs purely for weight loss.

The cost question nobody has settled

List prices for a year of treatment can run into the thousands of dollars, and many insurers have resisted covering the drugs for weight loss alone, citing cost projections that would strain their budgets if even a modest share of eligible members sought a prescription. Some employers have added coverage as a recruiting tool; others have explicitly excluded it, creating a patchwork where access depends heavily on which job a patient happens to hold.

“We finally have a drug that works. The entire healthcare system was not built to pay for something this effective at this scale.”

Longer-term questions remain open too, including what happens when patients stop taking the medication, since much of the lost weight tends to return without continued treatment — turning what was pitched as a course of treatment into what may functionally be a lifelong prescription, with lifelong costs to match.